Table 3.
Mutually adjusted factors associated with shift to NOACS
| OR (95% CI) | p-value | |
|---|---|---|
| Age per 1 year increment | 0.992 (0.987; 0.997) | 0.003 |
| Female sex | 1.18 (1.07; 1.29) | 0.001 |
| Smoking | ||
| Never | 1.0 (ref.) | |
| Ever | 0.71 (0.61; 0.84) | < 0.001 |
| Unknown | 0.47 (0.31; 0.72) | < 0.001 |
| District of inhabitance | ||
| North | 1.0 (ref.) | |
| Sharon | 1.10 (0.94; 1.28) | 0.240 |
| South | 1.30 (1.13; 1.51) | < 0.001 |
| Center | 1.01 (0.87; 1.17) | 0.934 |
| Jerusalem/ Hashfela | 1.11 (0.97; 1.28) | 0.138 |
| Baseline comorbidity | ||
| CHADS2 score | ||
| 0 | 1.0 (ref.) | |
| 1 | 2.15 (1.72; 2.69) | < 0.001 |
| ≥ 2 | 2.81 (2.23; 3.53) | < 0.001 |
| Hyperlipidemia | 1.45 (1.26; 1.66) | < 0.001 |
| Concomitant medications | ||
| ARBs | 1.26 (1.14; 1.39) | < 0.001 |
| Antithrombotics | 1.15 (1.03; 1.29) | 0.014 |
| Ca channel blockers | 0.92 (0.83; 1.01) | 0.090 |
| Diuretics | 0.84 (0.72; 0.98) | 0.024 |
| Nitrates | 0.63 (0.39; 1.02) | 0.062 |
| Incident 2012–2015 | 1.73 (1.52; 1.98) | < 0.001 |
NOAC new oral anticoagulants, SES socioeconomic status, ACE angiotensin converting enzyme, ARB angiotensin receptor blocker, SD standard deviation, CHADS congestive heart failure, hypertension, age>75, diabetes mellitus, stroke/transient ischemic event; scale of 0 (lowest risk) to 6 (highest risk). CHA2DS2-VASc Congestive heart failure, hypertension, age, diabetes mellitus, stroke/transient ischemic event, sex, vascular disease history; scale of 0 (lowest risk) to 9 (highest risk)
Bold means statistically significant, i.e. p < 0.05